Multiple Sclerosis - Drug Pipeline Landscape, 2023

Multiple Sclerosis (MS) is an autoimmune disorder in which the immune system attacks the myelin sheath that surrounds and protects the nerve fibers, causing inflammation eventually affecting the brain, spinal cord and optic nerves which disrupts the flow of information within the brain, and between the brain and body. It can be of four types: Clinically Isolated syndrome, Relapsing-remitting Multiple Sclerosis, Secondary progressive Multiple Sclerosis and Primary progressive Multiple Sclerosis.

The exact cause of Multiple Sclerosis is still unclear but the risk factors include family history, genetic factors, vitamin D and B12 deficiency, age, obesity, smoking, infections, other autoimmune diseases.

The most common symptoms of Multiple Sclerosis include spasticity/muscle spasms, pain, muscle weakness, numbness, fatigue, tingling, blurred or poor vision, cognitive and mood disturbances, balance and co-ordination issues.

Multiple Sclerosis can be diagnosed by the doctors with a physical and neurological examination, with questions of symptoms and medical history. Diagnostic tests include blood tests, spinal tap (lumbar puncture), MRI scans, spinal fluid analysis, evoked potential tests, optical coherence tomography.

The most common treatments options for Multiple Sclerosis are disease-modifying therapies, interferon beta medications, monoclonal antibodies, stem cell therapy, plasma exchange.

Report Highlights

Global Insight Service’s, "Multiple Sclerosis - Drug Pipeline Landscape, 2023" report provides an overview of the Multiple Sclerosis pipeline drugs. This report covers detailed insights on Multiple Sclerosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Multiple Sclerosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy

Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.

Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.

Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.

Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.